Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/4571
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJelagat, Mercy Karoney-
dc.date.accessioned2021-06-03T08:23:57Z-
dc.date.available2021-06-03T08:23:57Z-
dc.date.issued2019-
dc.identifier.urihttp://ir.mu.ac.ke:8080/jspui/handle/123456789/4571-
dc.description.abstractBackground: Tenofovir Disoproxil Fumarate (TDF) is the most widely used Anti- Retroviral Therapy (ART) drug due to its potency, safety profile and WHO recommendation. TDF causes proximal tubular renal dysfunction (PTRD) leading to Fanconi syndrome, acute kidney injury and chronic kidney damage. Modest rates of about 2-4% of TDF related toxicity based on estimated Glomerular Filtration Rate (GFR) have been described; while TDF induced PTRD has been reported to be 22%. Beta 2-microglobulin (B2M) in urine has been validated as a highly sensitive/specific marker for tubular proteinuria. TDF toxicity is more likely among African patients, it is reversible and TDF may be renal dosed in patients with dysfunction. Objectives: To assess proximal tubular renal dysfunction, global renal function and their determinants among patients on TDF versus TDF sparing regimen. Methods: This was a cross sectional study among HIV infected patients attending Academic Model Providing Access to Healthcare (AMPATH) program. The primary outcome of interest in this study was PTRD while the secondary outcome of interest was estimated GFR. PTRD was defined as any two of beta 2 microglobulin in urine, metabolic acidosis, normoglycemic glucosuria and fractional excretion of phosphate. Student t test, chi square, likelihood ratio and their non-parametric equivalents were used to test for statistical significance. Univariate and Multivariate logistic regression analysis was carried out. Results: A total of 516 participants were included in the final analysis, 261 on TDF while 255 were on non-TDF based regimens. The mean (SD) age of all participants was 41.5 (12.6) years with majority being female (60.3%). The proportion of PTRD was 10.0% versus 3.1% in the TDF compared to TDF-sparing group (P<0.001). Mean estimated GFR was 112.8 (21.5) vs 109.7 (21.9) ml/min/1.73mm3 (P=0.20) for the TDF compared to TDF-sparing group. TDF users were more likely to have PTRD compared to those not using TDF, adjusted Odds Ratio (AOR) 3.0, 95% CI 1.12 to 7.75. Hypophosphatemia was found to have a specificity of 88.8% and a low sensitivity of 23.5% in detecting proximal tubulopathy. Conclusion: There was significant tubulopathy in HIV patients on TDF compared to TDF-sparing group without significant difference in estimated GFR. The clinical significance of these findings may not be clear in the short term. Serum phosphate levels are not useful as a proxy for detecting tubular dysfunction.en_US
dc.description.sponsorshipEuropean and Developing Countries Clinical Trials Partnership (EDCTP)en_US
dc.language.isoenen_US
dc.publisherMoi Universityen_US
dc.subjectProximal tubularen_US
dc.subjectRenal dysfunctionen_US
dc.subjectHIV patientsen_US
dc.subjectTenofoviren_US
dc.subjectWestern Kenya.en_US
dc.subjectTenofovir sparing regimenen_US
dc.titleProximal tubular renal dysfunction among hiv patients on tenofovir versus tenofovir sparing regimen in Western Kenya.en_US
dc.typeThesisen_US
Appears in Collections:School of Medicine

Files in This Item:
File Description SizeFormat 
Dr. Karony Mercy Jelagat 2020.pdf657.03 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.